Part 4. What It Means to Combine Medications

When you first start taking Parkinson’s medication, you watch the effect of a single pill.

Did the body feel better than before the dose? How long did it take for the effect to appear? How many hours could you move?

Early on, questions at this level may be enough.

But once the disease progresses and motor fluctuations begin, the picture changes. You have to take the next pill before the effect of the last one has ended, and fast-acting and slow-acting drugs overlap within the same day. On top of that come dopamine agonists, MAO-B inhibitors, COMT inhibitors, and drugs like amantadine.

From this point on, treatment stops being about choosing one pill and becomes about designing the curve that several drugs create across the whole day.

For a long time, I looked at each drug one at a time.

How fast does Perkin work? How long does Madopar HBS last? How much does Ongentys extend the drug effect? How much does amantadine reduce dyskinesia?

But in the actual body, the drugs did not move separately.

The next dose came up while the previous one still remained, and the extended-release drug taken in the morning affected the afternoon’s curve. A drug used to extend the medication effect reduced OFF on some days, but on other days it lengthened the declining phase.

In the end, combining medications was not a matter of listing several drug names.

It was a matter of deciding how to bring together, within a single day, curves that each had a different speed, height, and duration.

Chapter 18. A drug does not act alone

The package insert lists each drug’s duration of action and half-life. But in a real patient’s day, it is rare for only one drug to be moving at a time.

You take a fast-acting levodopa in the morning. A little later, the effect rises and the body begins to move. But by then, the extended-release levodopa taken alongside it is already being absorbed slowly.

If the extended-release effect rises around the time the fast effect is coming down, the two curves can join naturally.

Fast-acting formulation → rises first

Extended-release formulation → rises later

The two curves overlap and support the next stretch

When this combination lines up well, it can avoid a sharp decline and extend a good ON.

But if the two drugs’ peaks overlap closer together in time than expected, the picture changes.

If enough of the fast-acting drug’s effect still remains when the extended-release drug also rises, the combined curve can climb above the therapeutic window. Dyskinesia can result.

Conversely, if the gap between the two drugs is too wide, a trough opens up in between. The fast drug has already come down while the slow drug has not yet risen.

During that stretch, the patient can experience OFF or incomplete ON.

So what matters in a combination is not each drug’s effect on its own, but the time at which the effects meet.

Chapter 19. Fast-acting and slow-acting drugs play different roles

I once thought of fast-acting levodopa and extended-release levodopa as roughly the same drug at different doses.

But using them in practice, the two formulations play different roles.

The fast-acting formulation is better at pulling the body up into ON. It is absorbed relatively quickly and helps you climb out of a deep OFF. But its rise and fall are pronounced, and its duration of action can be short.

The extended-release formulation rises slowly and lingers. It cannot pull the body up immediately the way the fast-acting formulation does, but it can help support an ON that already exists, or fill in the trough between doses.

I thought of this using a car as an analogy.

The fast-acting formulation is like the gas pedal.

The extended-release formulation is closer to cruise control.

If you need to get moving but only use cruise control, it feels frustratingly slow. If you keep pressing only the gas pedal, the speed swings widely.

The question is not which one is better.

What matters is which role is needed right now.

Do I need to climb out of a deep OFF? Do I need to hold an ON that already exists? Do I need to fill the trough that opens before the next dose? Do I need to get through a long gap at night or in the early morning?

Even with the same levodopa, the formulation’s role changes depending on the goal.

Chapter 20. The heart of a combination is peak and trough

Using several drugs together changes the height of the overall curve.

Think of the highest point of the drug effect as the peak, and the lowest point as the trough.

At first it’s easy to assume that raising the peak will make the body feel better. And in truth, a patient whose medication is insufficient does need an adequate peak. If the drug effect never crosses the therapeutic threshold, incomplete ON or ON failure can keep recurring.

But once motor fluctuations and dyskinesia appear, simply raising the peak can become a problem.

If the peak is too high, dyskinesia appears. But if you lower the overall drug effect too much, the trough drops along with it and OFF deepens.

So the treatment goal is not simply to build a high peak.

It is to lower an excessively high peak and raise an excessively low trough, narrowing the overall swing across the day.

A curve that climbs high and drops deep may be less useful for daily life than a curve that stays a bit lower but holds steady longer.

What I want is not to hit an output of 100 a few times a day.

It is to hold, for as long as possible, a state where I can walk, work, eat, and get to the bathroom.

Chapter 21. Two sides of “extending the drug effect”

COMT inhibitors and MAO-B inhibitors can help the effect of levodopa or dopamine last longer.

Just hearing the explanation, a longer-lasting drug effect sounds like it should always be a good thing.

But in the body, extension does not always mean the same thing.

A good ON can get longer. OFF before the next dose can shrink. The trough in the levodopa curve can become shallower.

In other cases, though, a high drug effect can be sustained longer and dyskinesia can increase. As the decline stretches out, you can also end up lingering longer in an ambiguous transition zone that is neither ON nor OFF.

Experiencing this myself, I learned one thing.

A drug effect lasting longer and a good state lasting longer are not necessarily the same thing.

You have to look at what, exactly, was extended.

Was a good ON extended? Was dyskinesia extended? Did incomplete ON get longer? Did the uncomfortable transition down into OFF grow longer?

So when evaluating a medication-extending drug, it is not enough to just look at how long you held on until the next dose.

You have to record what state the body was in during that time as well.

Chapter 22. Non-levodopa drugs change the baseline of the curve

Parkinson’s disease treatment uses several kinds of drugs besides levodopa.

Dopamine agonists stimulate dopamine receptors and can provide a baseline effect over a relatively long stretch of time. MAO-B inhibitors inhibit the breakdown of dopamine. COMT inhibitors extend the effect of levodopa. Amantadine is sometimes used specifically to reduce levodopa-induced dyskinesia.

None of these drugs moves in the same way levodopa does.

With levodopa, the relationship between taking the dose and the change in symptoms often feels fairly clear. Other drugs, by contrast, can act by changing the floor of the day’s curve or the character of the response.

So a patient might say:

“I don’t know if this drug makes me feel better right away.”

But not feeling an immediate rise doesn’t mean the drug has no role. The depth of OFF can lessen, the gap between levodopa doses can become easier to tolerate, or the intensity of dyskinesia can change.

Conversely, if the baseline effect becomes too strong, side effects such as drowsiness, dizziness, hallucinations, swelling, or impulse control problems can appear.

Dopamine agonists in particular should not be evaluated by motor symptoms alone. Non-motor domains such as sleep, psychiatric symptoms, impulsivity, and blood pressure need to be watched as well.

Combining medications is not just about adjusting the motor curve. It is about adjusting the whole person.

Chapter 23. When interval matters more than dose

When the drug effect feels insufficient, the first idea that comes to mind is usually to increase the amount taken at one time.

But increasing a single dose can raise the peak. ON can become stronger, but dyskinesia and side effects can increase too.

Another approach is to adjust the dosing interval.

Taking a large dose infrequently can widen the curve’s swings. Splitting it into smaller doses at more suitable intervals, on the other hand, may reduce the gap between peak and trough.

But making the interval too short can cause the next dose to keep overlapping with the previous one while it still remains, building up an unexpected accumulation.

Especially when an extended-release formulation or a medication-extending drug is being used alongside, an extra dose taken based only on the symptom in front of you can end up overlapping with another drug hours later.

Right after taking it, there was no change.

So I thought the dose was insufficient and took more.

But if the first dose was simply absorbing late, the two doses can end up rising together later on, building a high peak.

So dose and interval cannot be considered separately.

How much I took and when I took it are one and the same question.

Chapter 24. Medication carries over from the day before

I used to think of a day’s medication response as starting with the first morning dose.

But a real day does not cut off at midnight.

How much of the previous evening’s dose remains, how long the overnight dopamine gap was, how much sleep you got, and whether you had a late-night snack or protein — all of these change where the morning starts from.

A morning that starts at output 10 and a morning that starts at output 40 can respond differently to the same morning dose.

On a day with a low starting point, crossing the therapeutic threshold takes more time and more drug effect. On a day with a high starting point, even the usual dose can build a higher peak than expected.

So combining medications is not simply a timetable.

It is a 24-hour structure that connects the previous evening to the next morning.

When the morning dose isn’t working well, it’s not enough to look only at the morning dose — you have to look at the previous night’s last dose and the overnight gap together.

Chapter 25. Meals and the gut are an invisible part of the combination

Food and bowel motility do not appear on the prescription, but they are important variables in the actual drug-effect curve.

Levodopa is not absorbed directly in the stomach; it moves to the small intestine and is absorbed there. If gastric emptying is delayed, the onset of the drug effect can be delayed too.

Constipation, overeating, a high-fat meal, lack of sleep, stress, and the gastrointestinal motility changes of Parkinson’s disease itself can all have an effect.

Protein can compete with levodopa in the gut and at the blood–brain barrier. Not every patient is affected to the same degree, but if a delayed drug effect keeps recurring after a particular meal, it’s worth recording the timing relationship.

In the end, the real combination doesn’t consist of drugs alone.

It is medication + meals + bowel motility + sleep + activity level + that day’s starting point, all together.

So even with the same prescription, the outcome of the day can differ.

Chapter 26. Why an add-on dose is such a hard call

When OFF comes on, you want to get out of it fast.

When your body is stiff and your feet won’t lift off the floor, waiting feels unbearably long. So you start thinking about an extra dose of levodopa.

But there are questions an add-on dose absolutely requires you to check first.

Has the previous drug effect fully ended? Or has it simply not been absorbed yet? Is it declining right now? Has it already started rising again? Is an extended-release dose rising behind it?

Depending on the answers, the very same add-on dose can produce completely different results.

When the drug effect is genuinely insufficient, an add-on dose can bring you out of OFF. But when the previous dose is simply delayed, the two curves can end up overlapping late and creating dyskinesia.

So when the drug effect is late, I’ve learned to think about the direction of the curve first, rather than simply asking “should I take more?”

Am I stalled right now? Is there any sign of a rise, even a small one? Did the output move from 20 to 30? Has there been a small change in muscle tension or in how I walk?

A very small change can be an important clue in deciding whether to take an add-on dose.

But this is by no means a suggestion that patients should adjust their own medications on their own. Adding, reducing, or stopping Parkinson’s disease medication can cause side effects and serious changes in condition, so it must be discussed with the treating medical team.

The point of keeping records is not to prescribe for yourself, but to adjust the prescription together, with more accurate information.

Chapter 27. A good combination is not a combination with more drugs

As the number of drugs increases, the number of roles each drug covers increases too.

But having more drugs does not, by itself, mean more sophisticated treatment.

Adding a new drug needs a clear purpose.

Is it to reduce morning delayed ON? Is it to reduce wearing-off between doses? Is it to reduce nighttime OFF? Is it to reduce peak-dose dyskinesia? Is it to reduce OFF dystonia?

Changing several drugs at once without a clear purpose makes it hard to tell what actually worked and what caused the side effect.

A combination is not addition.

Adding one drug can change the role and required amount of the others. Adding a medication-extending drug can strengthen the effect of the existing levodopa, and using a dyskinesia drug to reduce dyskinesia can make other symptoms, previously hidden, more visible.

So when changing a combination, changing one variable at a time where possible, and observing it for long enough, helps with interpreting the result.

The body can’t be held constant like a laboratory, but you should at least know what was changed.

Chapter 28. The combination becomes visible only through records

Judging the drug effect from memory alone is difficult.

Moments when OFF was deep stick in memory strongly. Days when dyskinesia was severe also stay with you. But the ordinary, stable stretches of time are not remembered well.

So without records, treatment can end up swayed around the moments that were hardest, rather than the full picture.

The time the dose was taken. The type and amount of the drug. The time the first sign of effect appeared. The time the best state was reached. The time dyskinesia or dystonia appeared. The time it started falling again. Variables such as meals, sleep, and constipation.

Overlaying these records across several days, you begin to see not a single event but a recurring structure.

Does the start run late every morning? Does the noon dose’s peak overlap with the morning extended-release dose? Does a deep trough appear every evening? Does ON failure keep recurring after a particular meal? Does dyskinesia appear at the peak, or during the rise and fall?

A medication combination is not completed on the prescription.

Only when the prescription and the body’s response are recorded together does the real combination come into view.

Chapter 29. Finding the curve that fits me

There is no perfect timetable in Parkinson’s disease drug therapy that applies identically to everyone.

Even taking the same drug at the same dose, absorption speed differs, the stage of disease differs, and the threshold at which dyskinesia appears differs. Some patients find OFF far harder to bear than a little dyskinesia; others find dyskinesia harder to tolerate than OFF.

Life goals differ too.

Some people need to move quickly in the morning. Some need to work through the afternoon. For some, safely getting to the bathroom at night matters most of all.

A good combination is not decided by textbook numbers alone.

It has to take into account when that person needs to move, which symptom they most want to avoid, and how much side effect they can tolerate.

So the optimal point in drug therapy is not simply a pharmacological optimum.

It is the point where that person’s life holds up the longest.

Closing Part 4

At first, I thought combining medications just meant taking several drugs together.

But living it in my own body, the combination turned out to be far more complicated than that.

Dividing the roles of the fast-acting and slow-acting drugs. Connecting the next dose before the previous one has come down. Avoiding a high peak while keeping the trough from going too deep. Extending the drug effect while watching whether the uncomfortable transition period is stretching too. Putting meals, bowel motility, and sleep onto the curve as well.

In the end, combining medications was not stacking pills.

It was combining time.

It means looking at the flow of the whole day rather than a single pill’s dose, and looking at the repeating pattern rather than a single success or failure.

I still haven’t found the perfect combination.

Maybe the perfect combination will never exist. The disease changes, the body changes, and life changes too.

So the combination is not an answer you settle once and finish with.

It is a process of continuing to revise it while watching how the body changes.

A combination that worked well today won’t necessarily make the same curve tomorrow. But as records accumulate, I can gradually come to know, at least, where I rise from, where I fall, and which drugs meet at which times.

From that point on, treatment stops being about blindly adding or cutting medication.

It becomes about making my day a little flatter.

A good combination is not the one that uses the most drugs.

Nor is it the one that climbs to the highest point.

It is the combination that protects, for as long as possible, the time I can move, and that carves out a livable path between deep OFF and dyskinesia too severe to bear.

I am still looking for that narrow path today.

Looking at the curve, not the drug’s name. Looking at the whole day, not a single peak. And recording the small signals my body sends.